Facts About mRNA Vaccines

Facts About mRNA VaccinesPeter A. Jensen2022-08-01T13:20:39+00:00

SAFETY and EFFICACY of mRNA VACCINES

mRNA vaccines are safe and effective. mRNA COVID-19 Vaccines Have Been Rigorously Evaluated for Safety. CDC
Both the Pfizer-BioNTech and Moderna COVID-19 vaccines are highly effective against both symptomatic and severe COVID-19 across age groups and in diverse populations. CDC/IDSA

HISTORY of mRNA VACCINES

mRNA Vaccines Are Newly Available to the Public But Have Been Studied for Decades CDC
Hundreds of scientists had worked on mRNA vaccines for decades before the coronavirus pandemic brought a breakthrough. Nature
How COVID unlocked the power of RNA vaccines. Nature

mRNA VACCINES and the COVID-19 PANDEMIC

Vaccines are estimated to have saved 20 million lives in one year from Dec. 2020 to Dec. 2021. The Lancet
67% of the world population has received at least one dose of a COVID-19 vaccine. 12.34 billion doses have been administered globally, and 7.89 million are now administered each day. Only 19.9% of people in low-income countries have received at least one dose. Our World Data
As of July 3, 2022, more than 3.6 billion Pfizer-BioNTech COVID-19 vaccines were shipped to 180 countries in every region of the world. Pfizer
Pfizer and Moderna forecast to almost double vaccine sales in 2022. Bullish projections show mRNA jab producers could generate more than $90bn in sales next year FT
Moderna expects $17 billion to $22 billion in total COVID-19 vaccine sales in 2022. Fierce Pharma

CLINICAL TRIALS for mRNA VACCINES

212 mRNA Vaccines Clinical Trials are recorded by U.S. National Library of Medicine. ClinicalTrials.Gov

mRNA is NATURE. mRNA is LIFE.

DNA is in every cell of every body. All life on earth functions with DNA, mRNA and proteins.
- Deoxyribonucleic acid (DNA) is an organic chemical that contains genetic information and instructions for protein synthesis. DNA is the foundation of all living organisms on earth.
mRNA molecules are generated from DNA to express proteins.
- Messenger RNA (mRNA) is a type of single-stranded RNA involved in protein synthesis. mRNA is made from a DNA template during the process of transcription. The role of mRNA is to carry protein information from the DNA in a cell’s nucleus to the cell’s cytoplasm, where the protein-making organelle (the ribosome) reads the mRNA sequence and translates each three-base codon into its corresponding amino acid into an organic protein molecule.
Proteins in the body are naturally manufactured by translation of DNA into mRNA, into proteins.

The Laws of Nature are not patentable – not a monopoly – and neither are personal DNA (genes). For example, SUPREME COURT OF THE UNITED STATES decisions 2011 and 2012 under 35 U.S. Code § 101.

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.Peter A. Jensen2023-02-03T11:00:00+00:00

Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax AbstractPeter A. Jensen2022-08-31T11:50:39+00:00

Normax Abstract

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.